CD1D and neoplasm: The anti-tumor activity of CD1d-restricted lipid targeted αβ-TCR invariant natural killer T cells (iNKT) cells has already been established in preclinical model systems, and is also being investigated clinically, for example for hepatocellular carcinoma (NCT04011033).